nach oben

Erschienen in:

01.03.2011

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

verfasst von: Oliver Kepp, Lorenzo Galluzzi, Isabelle Martins, Frederic Schlemmer, Sandy Adjemian, Mickael Michaud, Abdul Qader Sukkurwala, Laurie Menger, Laurence Zitvogel, Guido Kroemer

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The success of some chemo- and radiotherapeutic regimens relies on the induction of immunogenic tumor cell death and on the induction of an anticancer immune response. Cells succumbing to immunogenic cell death undergo specific changes in their surface characteristics and release pro-immunogenic factors according to a defined spatiotemporal pattern. This stimulates antigen presenting cells such as dendritic cells to efficiently take up tumor antigens, process them, and cross-prime cytotoxic T lymphocytes, thus eliciting a tumor-specific cognate immune response. Such a response can also target therapy-resistant tumor (stem) cells, thereby leading, at least in some instances, to tumor eradication. In this review, we shed some light on the molecular identity of the factors that are required for cell death to be perceived as immunogenic. We discuss the intriguing observations that the most abundant endoplasmic reticulum protein, calreticulin, the most abundant intracellular metabolite, ATP, and the most abundant non-histone chromatin-binding protein, HMGB1, can determine whether cell death is immunogenic as they appear on the surface or in the microenvironment of dying cells.

Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008). Immunological aspects of cancer chemotherapy. Nat Rev Immunol, 8(1), 59–73.PubMedCrossRef

Savill, J., & Fadok, V. (2000). Corpse clearance defines the meaning of cell death. Nature, 407(6805), 784–788.PubMedCrossRef

Matzinger, P. (2002). The danger model: a renewed sense of self. Science, 296(5566), 301–305.PubMedCrossRef

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., et al. (2009). Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ, 16(1), 3–11.PubMedCrossRef

Zou, W. (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol, 6(4), 295–307.PubMedCrossRef

Rubio, M. T., Ittelet, D., Raymond, E., Blay, J. Y., Bernard, J., & Chouaib, S. (2004). The immunosuppressive effect of vincristine on allostimulatory potential of human dendritic cells interferes with their function and survival. Int J Oncol, 25(2), 407–412.PubMed

Zitvogel, L., Apetoh, L., Ghiringhelli, F., Andre, F., Tesniere, A., & Kroemer, G. (2008). The anticancer immune response: indispensable for therapeutic success? J Clin Invest, 118(6), 1991–2001.PubMedCrossRef

Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., et al. (2005). Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med, 202(12), 1691–1701.PubMedCrossRef

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J. L., et al. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med, 13(1), 54–61.PubMedCrossRef

10.

Jung, S., Unutmaz, D., Wong, P., Sano, G., De los Santos, K., Sparwasser, T., et al. (2002). In vivo depletion of cd11c+ dendritic cells abrogates priming of cd8+ t cells by exogenous cell-associated antigens. Immunity, 17(2), 211–220.PubMedCrossRef

11.

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., et al. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med, 13(9), 1050–1059.PubMedCrossRef

12.

Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., et al. (2007). The interaction between hmgb1 and tlr4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev, 220, 47–59.PubMedCrossRef

13.

Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., et al. (2009). Activation of the nlrp3 inflammasome in dendritic cells induces il-1beta-dependent adaptive immunity against tumors. Nat Med, 15(10), 1170–1178.PubMedCrossRef

14.

Banchereau, J., & Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature, 392(6673), 245–252.PubMedCrossRef

15.

Albert, M. L., Sauter, B., & Bhardwaj, N. (1998). Dendritic cells acquire antigen from apoptotic cells and induce class i-restricted ctls. Nature, 392(6671), 86–89.PubMedCrossRef

16.

Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009). Immunogenic and tolerogenic cell death. Nat Rev Immunol, 9(5), 353–363.PubMedCrossRef

17.

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883–899.PubMedCrossRef

18.

Zitvogel, L., Kepp, O., & Kroemer, G. (2010). Decoding cell death signals in inflammation and immunity. Cell, 140(6), 798–804.PubMedCrossRef

19.

Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., et al. (1996). Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med, 183(1), 87–97.PubMedCrossRef

20.

Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007). Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood, 109(11), 4839–4845.PubMedCrossRef

21.

Mukhopadhaya, A., Mendecki, J., Dong, X., Liu, L., Kalnicki, S., Garg, M., et al. (2007). Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Res, 67(16), 7798–7806.PubMedCrossRef

22.

Didelot, C., Lanneau, D., Brunet, M., Joly, A. L., De Thonel, A., Chiosis, G., et al. (2007). Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr Med Chem, 14(27), 2839–2847.PubMedCrossRef

23.

Locher, C., Rusakiewicz, S., Tesniere, A., Ghiringhelli, F., Apetoh, L., Kroemer, G., et al. (2009). Witch hunt against tumor cells enhanced by dendritic cells. Ann NY Acad Sci, 1174, 51–60.PubMedCrossRef

24.

Gardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., Murphy-Ullrich, J. E., et al. (2005). Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of lrp on the phagocyte. Cell, 123(2), 321–334.PubMedCrossRef

25.

Kepp, O., Gdoura, A., Martins, I., Panaretakis, T., Schlemmer, F., Tesniere, A., et al. (2010). Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic death. Cell Cycle, 9(15), 3072–3077.PubMedCrossRef

26.

Krause, K. H., & Michalak, M. (1997). Calreticulin. Cell, 88(4), 439–443.PubMedCrossRef

27.

Michalak, M., Corbett, E. F., Mesaeli, N., Nakamura, K., & Opas, M. (1999). Calreticulin: one protein, one gene, many functions. Biochem J, 344(Pt 2), 281–292.PubMedCrossRef

28.

Johnson, S., Michalak, M., Opas, M., & Eggleton, P. (2001). The ins and outs of calreticulin: from the er lumen to the extracellular space. Trends Cell Biol, 11(3), 122–129.PubMedCrossRef

29.

Bedard, K., Szabo, E., Michalak, M., & Opas, M. (2005). Cellular functions of endoplasmic reticulum chaperones calreticulin, calnexin, and erp57. Int Rev Cytol, 245, 91–121.PubMedCrossRef

30.

Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A. C., Chapman, D. C., et al. (2009). Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J, 28(5), 578–590.PubMedCrossRef

31.

Breckenridge, D. G., Stojanovic, M., Marcellus, R. C., & Shore, G. C. (2003). Caspase cleavage product of bap31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. J Cell Biol, 160(7), 1115–1127.PubMedCrossRef

32.

Kroemer, G., Galluzzi, L., & Brenner, C. (2007). Mitochondrial membrane permeabilization in cell death. Physiol Rev, 87(1), 99–163.PubMedCrossRef

33.

Kepp, O., Senovilla, L., Galluzzi, L., Panaretakis, T., Tesniere, A., Schlemmer, F., et al. (2009). Viral subversion of immunogenic cell death. Cell Cycle, 8(6), 860–869.PubMedCrossRef

34.

Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., Durchschlag, M., et al. (2008). The co-translocation of erp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ, 15(9), 1499–1509.PubMedCrossRef

35.

Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, D. L., & Henson, P. M. (1992). Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol, 148(7), 2207–2216.

36.

Tyurina, Y. Y., Basova, L. V., Konduru, N. V., Tyurin, V. A., Potapovich, A. I., Cai, P., et al. (2007). Nitrosative stress inhibits the aminophospholipid translocase resulting in phosphatidylserine externalization and macrophage engulfment: implications for the resolution of inflammation. J Biol Chem, 282(11), 8498–8509.PubMedCrossRef

37.

Tarr, J. M., Young, P. J., Morse, R., Shaw, D. J., Haigh, R., Petrov, P. G., et al. (2010). A mechanism of release of calreticulin from cells during apoptosis. J Mol Biol, 401(5), 799–812.PubMedCrossRef

38.

Latour, S., Tanaka, H., Demeure, C., Mateo, V., Rubio, M., Brown, E. J., et al. (2001). Bidirectional negative regulation of human T and dendritic cells by cd47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J Immunol, 167(5), 2547–2554.PubMed

39.

Oldenborg, P. A., Gresham, H. D., & Lindberg, F. P. (2001). Cd47-signal regulatory protein alpha (sirpalpha) regulates fcgamma and complement receptor-mediated phagocytosis. J Exp Med, 193(7), 855–862.PubMedCrossRef

40.

Castelli, C., Ciupitu, A. M., Rini, F., Rivoltini, L., Mazzocchi, A., Kiessling, R., et al. (2001). Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res, 61(1), 222–227.PubMed

41.

Gehrmann, M., Liebisch, G., Schmitz, G., Anderson, R., Steinem, C., De Maio, A., et al. (2008). Tumor-specific Hsp70 plasma membrane localization is enabled by the glycosphingolipid Gb3. PLoS ONE, 3(4), e1925.PubMedCrossRef

42.

Chen, T., Guo, J., Han, C., Yang, M., & Cao, X. (2009). Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol, 182(3), 1449–1459.PubMed

43.

Delamarre, L., Couture, R., Mellman, I., & Trombetta, E. S. (2006). Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. J Exp Med, 203(9), 2049–2055.PubMedCrossRef

44.

Shiratsuchi, A., Watanabe, I., Takeuchi, O., Akira, S., & Nakanishi, Y. (2004). Inhibitory effect of Toll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. J Immunol, 172(4), 2039–2047.PubMed

45.

Tesniere, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., et al. (2010). Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene, 29(4), 482–491.PubMedCrossRef

46.

Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002). Release of chromatin protein hmgb1 by necrotic cells triggers inflammation. Nature, 418(6894), 191–195.PubMedCrossRef

47.

Bell, C. W., Jiang, W., Reich, C. F., III, & Pisetsky, D. S. (2006). The extracellular release of hmgb1 during apoptotic cell death. Am J Physiol Cell Physiol, 291(6), C1318–1325.PubMedCrossRef

48.

Andersson, U., Wang, H., Palmblad, K., Aveberger, A. C., Bloom, O., Erlandsson-Harris, H., et al. (2000). High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med, 192(4), 565–570.PubMedCrossRef

49.

Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., et al. (1999). HMG-1 as a late mediator of endotoxin lethality in mice. Science, 285(5425), 248–251.PubMedCrossRef

50.

Bonaldi, T., Talamo, F., Scaffidi, P., Ferrera, D., Porto, A., Bachi, A., et al. (2003). Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J, 22(20), 5551–5560.PubMedCrossRef

51.

Gardella, S., Andrei, C., Ferrera, D., Lotti, L. V., Torrisi, M. R., Bianchi, M. E., et al. (2002). The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep, 3(10), 995–1001.PubMedCrossRef

52.

Sancho, D., Joffre, O. P., Keller, A. M., Rogers, N. C., Martinez, D., Hernanz-Falcon, P., et al. (2009). Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature, 458(7240), 899–903.PubMedCrossRef

53.

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., et al. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410(6832), 1107–1111.PubMedCrossRef

54.

Schroder, K., & Tschopp, J. (2010). The inflammasomes. Cell, 140(6), 821–832.PubMedCrossRef

55.

Franchi, L., Eigenbrod, T., Munoz-Planillo, R., & Nunez, G. (2009). The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol, 10(3), 241–247.PubMedCrossRef

56.

Latz, E. (2010). The inflammasomes: mechanisms of activation and function. Curr Opin Immunol, 22(1), 28–33.PubMedCrossRef

57.

Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., et al. (2009). Chemotherapy induces ATP release from tumor cells. Cell Cycle, 8(22), 3723–3728.PubMedCrossRef

58.

Ferrari, D., Pizzirani, C., Adinolfi, E., Lemoli, R. M., Curti, A., Idzko, M., et al. (2006). The P2X7 receptor: a key player in IL-1 processing and release. J Immunol, 176(7), 3877–3883.PubMed

59.

Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., et al. (2009). Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature, 461(7261), 282–286.PubMedCrossRef

60.

Stout, C. E., Costantin, J. L., Naus, C. C., & Charles, A. C. (2002). Intercellular calcium signaling in astrocytes via ATP release through connexin hemichannels. J Biol Chem, 277(12), 10482–10488.PubMedCrossRef

61.

Zhang, Z., Chen, G., Zhou, W., Song, A., Xu, T., Luo, Q., et al. (2007). Regulated ATP release from astrocytes through lysosome exocytosis. Nat Cell Biol, 9(8), 945–953.PubMedCrossRef

Titel: Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
verfasst von: Oliver Kepp
Lorenzo Galluzzi
Isabelle Martins
Frederic Schlemmer
Sandy Adjemian
Mickael Michaud
Abdul Qader Sukkurwala
Laurie Menger
Laurence Zitvogel
Guido Kroemer
Publikationsdatum: 01.03.2011
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2011
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-011-9273-4

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Tumor immunosurveillance in human cancers

Preface

Biography — Wolf H. Fridman, M.D., Ph.D.

Myeloid cell diversification and complexity: an old concept with new turns in oncology

How to improve the immunogenicity of chemotherapy and radiotherapy

The significant role of mast cells in cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie